HC Wainwright & Co. Initiates Coverage On Beam Therapeutics With Buy Rating, Announces Price Target of $80
HC Wainwright & Co. Initiates Coverage On Beam Therapeutics With Buy Rating, Announces Price Target of $80
華盛頓海明頓公司發起對beam therapeutics的買入評級，宣佈目標股價爲80美元。
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $80.
HC Wainwright & Co. 分析師Patrick Trucchio開始對beam therapeutics進行覆蓋，並給予買入評級，宣佈目標價格爲80美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。